ONCOLOGY Vol 33 No 8

Alan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer. 

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

Accuracy of current guidelines for genetic testing of breast cancer patients has been recently challenged by a pair of studies suggesting that these guidelines may miss as many patients with pathogenic variants (or genetic mutations) as they may catch.

ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.